Pelacarsen is a hepatocyte-directed ASO targeting liver LPA mRNA, and can significantly reduce Lp(a) production.321 In addition, another siRNA drug, olpasiran, also shows a strong Lp(a)-lowering effect.322 Taken together, existing evidence suggests that Lp(a) is a potential target to treat ASCVD, and drugs targeting it are under intense development. The gene discussed is LPA; the disease is atherosclerosis.